Betta Pharmaceuticals has been granted a patent for a specific salt and crystal form of a compound designed for pharmaceutical applications. The invention includes methods for preparing this compound and its use in treating various diseases and conditions. GlobalData’s report on Betta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Betta Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Betta Pharmaceuticals's grant share as of July 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Crystal form of a specific pharmaceutical compound
The granted patent US12043622B2 describes a novel crystal form of a specific compound, identified in the claims as Formula II. The patent outlines the unique characteristics of this crystal form, particularly its X-ray powder diffraction pattern, which features distinct peaks at specific diffraction angles (2?) including 4.4°, 8.7°, 10.8°, 18.4°, 23.6°, and 26.9°, with additional peaks noted in subsequent claims. The claims further detail the preparation methods for this crystal form, which involve suspending the compound in water or a water-soluble organic solvent, heating the suspension, and subsequently adding L-tartaric acid to facilitate an acidification treatment. The process concludes with cooling, filtering, and drying to yield the desired crystal form.
Additionally, the patent claims include alternative preparation methods, such as dissolving the compound in methanol and combining it with a solution of L-tartaric acid, followed by filtration and drying. The patent also encompasses a pharmaceutical composition that incorporates this crystal form, combined with pharmaceutically acceptable excipients, auxiliaries, or carriers, indicating its potential application in therapeutic settings. Overall, the patent provides a comprehensive framework for the synthesis and characterization of this specific crystal form, which may have implications for its use in pharmaceuticals.
To know more about GlobalData’s detailed insights on Betta Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
